Guinan E C, Gribben J G, Boussiotis V A, Freeman G J, Nadler L M
Division of Hematologic Malignancies and Pediatric Oncology, Dana Farber Cancer Institute, Boston, MA 02115.
Blood. 1994 Nov 15;84(10):3261-82.
The above story illustrates the translation of basic scientific discoveries to the clinic. In vitro and preclinical in vivo experimentation suggests that modulation of the B7:CD28 pathway will result in either amplification or suppression of the immune response. Considering the frequency with which diseases characterized by either inadequate or dysregulated immune function present to the practicing hematologist or oncologist, it is not difficult to envisage clinical applications for reagents that modulate this pathway. However, we still have much to learn about the function and clinical potential of this and other potentially redundant costimulatory pathways and therefore we suspect that this story will become considerably more complex over the next few years.
上述故事阐述了基础科学发现向临床的转化。体外及临床前体内实验表明，对B7:CD28通路的调控将导致免疫反应的增强或抑制。鉴于血液科医生或肿瘤内科医生所面对的以免疫功能不足或失调为特征的疾病的发生频率，不难设想调控该通路的试剂的临床应用。然而，对于这一以及其他可能存在冗余的共刺激通路的功能和临床潜力，我们仍有许多需要了解的地方，因此我们推测在未来几年这个情况将会变得更加复杂。
